Established in 2016 as a collaboration of Emory University, Morehouse School of Medicine, and the Georgia Institute of Technology, the mission of the Georgia Center for Diabetes Translation Research (GCDTR) is to promote translation and healthy equity research to impact practice, programs, and policy in Georgia and the Souteastern United States.
Is there a Place for Race in Precision Medicine?
Monday, May 16, 2022 | 12:00 NOON
Herman Taylor, MD, MPH, FACC, FAHA
Endowed Professor of Medicine & Director, Cardiovascular Research Institute, Morehouse School of Medicine
Our lastest seminar series presentation hosted by the Socio-ecological and Behavioral Science for Equity Core, featuring a talk by Herman Taylor, MD, MPH, FACC, FAHA. Herman Taylor is the Endowed Professor and Director of the Cardiovascular Research Institute at the Morehouse School of Medicine overseeing a diverse portfolio of cardiovascular research involving multiple interdisciplinary teams. Previously, he was the founding Director of the NIH’s landmark study of African American heart health and disease – the Jackson Heart Study – and the broad network of training programs, research centers and collaborations that the “Study” comprises.
Dr. Taylor’s current work at Morehouse School of Medicine continues a focus on the advancement of health equity. Through projects funded by the NSF, NIH, AHA, 23And Me, Google, Apple, the Truist Foundation, the NFL Players Association and others, he has led the CVRI to broaden its traditional focus on biomedical basic science and embrace an expanding use of the tools of clinical medicine, multiomics, mHealth applications, wearable and off-body sensors in combination with social epidemiology to more fully understand the sources of and solutions to health disparity and inequity. Community-based initiatives of the CVRI include observational intervention studies featuring mobile apps co-created with minority youth, coupled pipeline initiatives that create academic and economic opportunities among them.
His research has been featured in major scientific and lay publications, from Nature and Circulation to The New York Times and National Geographic. He has lectured internationally and given expert testimony to Senate and House Committees and the U.S. Commission on Civil Rights on health disparities and equity. He is a graduate of Princeton University, Harvard Medical School and the Harvard Chan School of Public Health and holds adjunct professorships at Emory School of Medicine and the Harvard Chan School of Public Health.
Current Funding Opportunities
Pilot Grant Program
GCDTR is seeking pilot grant proposals in the field of diabetes translation research that advances health equity. Faculty researchers from Emory University, Morehouse School of Medicine, and Georgia Institute of Technology are eligible to apply. Two levels of funding are available:
- Preliminary or formative research: This opportunity is for exploratory, feasibility, and formative diabetes health equity studies to generate preliminary data to facilitate a subsequent submission of a research grant for external funding. Examples include, but are not limited to, qualitative field work, community-engaged research for development of research questions, instrument, or assay testing, and secondary data analyses that leverage existing databases for data science, analytics, and modeling. Budget: up to $30,000 for one year.
- Prospective clinical or community-based studies: This opportunity is for pilot studies addressing diabetes health equity questions using prospective approaches in clinical or community-based settings to create or strengthen preliminary data to facilitate subsequent external grant submissions. A variety of methods may be used, including social, behavioral, clinical and community concepts, evaluations of clinical or innovative interventions, and dissemination and implementation studies. Budget: up to $50,000 for one year.
Letter of intent due: January 22, 2002
Application deadline: April 1, 2022
For more infomation, click here.
Micro Grant Rapid Funding Mechanism
The Georgia Center for Diabetes Translation Research (GCDTR) is pleased to announce a Micro Grant Rapid Funding Mechanism (MGRFM). This is a unique competitive opportunity being offered by the GCDTR to provide timely and critical resources that can be leveraged by investigators for the submission of larger research funding requests. Award amounts will range from $500 to $2,000. The MGRFM grants will support diabetes translation research leading to the submission of an NIH (preferably) or other extramural research funding application that addresses themes encompassed in GCDTR’s research cores (www.gcdtr.org/core-programs/).
Funds are intended to be used to:
- Enable a new NIH or other extramural application that is expected to be submitted within the next 6 to 12 months
- Gather data needed for a scored NIH or other extramural application that is currently being revised for resubmission
For more information, click here.
Incidence and Pathophysiology of Diabetes in South Asian Adults Living in India and Pakistan Compared with US blacks and Whites
Narayan KMV, Kondal D, Kobes S, Staimez LR, Mohan D, Gujral UP, Patel SA, Anjana RM, Shivashankar R, Ali MK, Chang HH, Kadir M, Prabhakaran D, Daya N, Selvin E, Tandon N, Hanson R, Mohan V.
BMJ Open Diabetes Research & Care - 2021;9:3001988.
South Asians (SA) and Pima Indians have high prevalence of diabetes but differ markedly in body size. The pathophysiology of type 2 diabetes in non-obese South Asians may imply the need to investigate strategies at improving insulin secretion for diabetes prevention.
Preparedness cycle to address transitions in diabetes care during the COVID-19 pandemic and future outbreaks
Unjali P. Gujral, Leslie Johnson, Jannie Nielsen, Priyathama Vellanki, J. Sonya Haw, Georgia M. Davis, Mary Beth Weber, Francisco J. Pasquel
BMJ Open Diabetes Research & Care - 2020 Jul;8(1):e001520.
The authors describe how to respond to the public health crisis focused on diabetes care in the USA. They present strategies to address and evaluate transitions in diabetes care occurring in the immediate short-term (ie, response and mitigation), as well as phases to adapt and enhance diabetes care during the months and years to come while also preparing for future pandemics (ie, recovery, surveillance, and preparedness).
Rodolfo J. Galindo, Grazia Aleppo, David C. Klonoff, Elias K. Spanakis, Shivani Agarwal, Priya Vellanki, Darin E. Olson, Guillermo E. Umpierrez, Georgia M. Davis, Francisco J. Pasquel
Journal of Diabetes Science and Technology - 2020 Jul;14(4):822-832.
In this commentary, the authors analyze the answers to six questions about what is needed to bring CGM into the hospital as a reliable, safe, and effective tool, especially with regard to those patients with COVID-19.